77 search results for lung cancer
NCCN Guidelines for Patients with Permission Email
Myeloid Leukemia Colon Cancer Esophageal Cancer Head and Neck Cancers: Nasopharyngeal Cancer Oral Cancers Oropharyngeal Cancer Hepatobiliary Cancers: Liver Cancer Gallbladder and Bile Duct Cancers Hodgkin Lymphoma Kidney Cancer Lung Cancer: Early and Locally Advanced Metastatic Malignant, e a a n d Vomiting Cancer Screening Lung Cancer Screening Age-Related Adolescents and Yo u n g, Invasive Metastatic Colon Cancer Kidney Cancer Lung Cancer: Early and Locally Advanced
https://www.nccn.org/docs/default-source/patient-resources/nccn-guidelines-for-patients-with-permission-email.pdf?sfvrsn=94769ebd_2NCCN Guidance on Inclusive Language
cancer rather than a lung cancer patient ). An illness or disease is something individuals have (ie, Language Guide. International Association for the Study of Lung Cancer; 2021. Available at: https, Version 2.0 | April 25, 2025 © 2025 National Comprehensive Cancer Network® (NCCN®) NCCN, Guidance Version 2.0 April 25, 2025 Page 2 of 10 © 2025 National Comprehensive Cancer Network, Version 2.0 April 25, 2025 Page 3 of 10 © 2025 National Comprehensive Cancer Network® (NCCN
https://www.nccn.org/docs/default-source/about/nccn-guidance-on-inclusive-language.pdf?sfvrsn=53c8c78f_2Guidelines for Patients
Liver Cancer Version: 2023 Lung Cancer, Version: 2022 Non-Small Cell Lung Cancer - Early and Locally Advanced Version: 2024 Non-Small Cell Lung Cancer, Version: 2024 Small Cell Lung Cancer, Cancer Version: 2023 Adrenal Tumors
https://www.nccn.org/guidelines/patientsNCCN-2025-Annual-Conference-Exhibit-Guide
• Fatigue and Cancer • Follicular Lymphoma • Gallbladder and Bile Duct Cancers, Inhibitors • Kidney Cancer • Liver Cancer • Lung Cancer Screening • Mantle Cell Lymphoma • Marginal, and Vomiting • Neuroendocrine Tumors • Non-Small Cell Lung Cancer: Early and Locally Advanced • Non-Small Cell Lung Cancer: Metastatic • Ovarian Cancer • Palliative Care • Pancreatic Cancer, Bowel Adenocarcinoma • Small Cell Lung Cancer • Soft Tissue Sarcoma • Squamous Cell Skin Cancer
https://www.nccn.org/docs/default-source/education-research/nccn-2025-annual-conference-exhibit-guide.pdf?sfvrsn=5765e4e8_5Treatment by Cancer Type
Treatment by Cancer Type, Version: 1.2025 Non-Small Cell Lung Cancer, Small Cell Lung Cancer Version: 4.2025, . NCCN Guidelines Treatment by Cancer Type, Version: 3.2025 Basal Cell Skin Cancer, Version: 2.2025 Biliary Tract Cancers
https://www.nccn.org/guidelines/category_130 Years of NCCN
for the treatment of cancer and perform outcomes research – and so the NCCN was born. With 13 original NCCN Member, with cancer across the country. Now an alliance of 33 leading cancer centers, NCCN develops resources, as a national alliance to develop and institute standards of care for the treatment of cancer and perform, published to assist in the decision-making process of individuals involved in cancer care to improve patient care and outcomes. The first disease types available were: Acute Leukemia and Breast, Colon, Lung
https://www.nccn.org/home/about/nccn-history/30-years-of-nccnAbout the NCCN Guidelines for Patients
than 25 years, the National Comprehensive Cancer Network® (NCCN®) has developed resources to improve the quality of cancer care. These resources include the award-winning NCCN Guidelines for Patients, discuss options with their cancer care team. This library of free resources is made possible through, for their ability to empower people with cancer and caregivers. Recent Awards, Annual Communicator Award of Distinction for the NCCN Guidelines for Patients: Kidney Cancer
https://www.nccn.org/patientresources/patient-resources/about-the-nccn-patient-guidelinesPAS Policy Report Precision Medicine Final
for the appropriate biomarker tests. Lung and other cancers require significant surgical intervention, and Implications for Quality, Accessible, and Equitable Cancer Care In recent years, targeted medicines have offered dramatic advancements in cancer care outcomes across a wide variety of cancer types. However, as cancer care becomes increasingly personalized, access to biomarker testing and targeted, , the National Comprehensive Cancer Network (NCCN ® ) conducted a patient advocacy scan
https://www.nccn.org/docs/default-source/oncology-policy-program/pas-policy-report-precision-medicine-final.pdf?sfvrsn=468e4a2b_1NCCN 2025 Annual Conference Exhibit Floor Plan
........................................A17 Global Colon Cancer Association ..............A-16 GO2 for Lung Cancer, EXHIBITORS American Cancer Society ............................ 426 Astellas Pharma Inc, of the National Comprehensive Cancer Network ................. 407 Johnson & Johnson, Cancer Center................................. 404 Novartis Pharmaceuticals Corp.................. 124, .................................................... 121 *Roswell Park Comprehensive Cancer Center
https://www.nccn.org/docs/default-source/education-research/ac-floor-plan2025.pdf?sfvrsn=4bda3034_11Submission Request Form
Lymphomas - 2.2025 Biliary Tract Cancers - 1.2025 Bladder Cancer - 1.2025 Bone Cancer - 2.2025 Breast, Cancer-Related Fatigue - 2.2025 Castleman Disease - 2.2025 Central Nervous System Cancers - 5.2024, Cancers - 2.2025 Gastric Cancer - 2.2025 Gastrointestinal Stromal Tumors - 2.2024 Genetic/Familial, - 2.2025 Kidney Cancer - 3.2025 Lung Cancer Screening - 1.2025 Management of Immunotherapy-Related, and Adrenal Tumors - 1.2025 Non-Small Cell Lung Cancer - 3.2025 Occult Primary - 2.2025 Older
https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-formAsia
at NCCN.org), as well as Chinese translations. Visit nccnchina.org.cn Chinese Gynecologic Cancer Society (CGCS): In collaboration with the Chinese Gynecologic Cancer Society (CGCS) and Shanghai Yanxin Cultural Firm, NCCN will work with the leading cancer care experts in China to translate and adapt NCCN Guidelines for Gynecologic Cancers, including cervical Cancer, Ovarian Cancer, Uterine Neoplasms, Gestational Trophoblastic Neoplasia, and Vulvar Cancer. China Editions of NCCN Guidelines
https://www.nccn.org/global/global-program/asiaWebinars for Patients
Small Cell Lung Cancer - Recording coming soon! Why Should I Consider a Clinical Trial? (2025) Non-Small Cell Lung Cancer (NSCLC) (2025) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (2024) Myeloproliferative Neoplasms (MPN) (2024) Breast Cancer Screening (2024) Advanced, webinars, webinar, patient resources, breast cancer, lung cancer, recorded webinars, recorded patient, NCCN provides free webinars for people affected by cancer and caregivers. These live
https://www.nccn.org/patientresources/patient-resources/patient-webinarsYoung Investigator Awards
Comprehensive Cancer Center Novel Combination Therapy for Colorectal and Esophagogastric Cancers, Intervention Mapping to Improve Lung Cancer Screening Among Black Veterans Ravi Parikh, MD, MPP, . Young Investigator Awards The National Comprehensive Cancer, investigators from NCCN Member Institutions represent tomorrow’s leaders for advancing cancer care. The NCCN, , MD, Dana-Farber/Brigham and Women’s Cancer Center | Mass General Cancer Center A Phase II Sudy
https://www.nccn.org/education-research/nccn-oncology-research-program/young-investigator-awardsYoung Investigator Awards
Comprehensive Cancer Center Novel Combination Therapy for Colorectal and Esophagogastric Cancers Zachary, Neelima Navuluri, MD, MPH, Duke Cancer Institute Intervention Mapping to Improve Lung Cancer, The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation® each, tomorrow’s leaders for advancing cancer care. The NCCN Oncology Research Program (ORP) manages, . Recent YIA Recipients 2025 Rachel Abelman, MD, Dana-Farber/Brigham and Women’s Cancer
https://www.nccn.org/patientresources/patient-resources/nccn-foundation/young-investigator-awardsThe Impact of Policy Regulation on Guideline-Concordant Care Globally Summary Article
specific cancers. One significant step to reduce cancer incidence is to eliminate tobacco usage, based on the WHO EML for cancers with the highest incidence in LLMICs. These cancers include lung, of patients with cancer lack access to essential medicines, crucial health infrastructure, and coordinated multidisciplinary cancer care. One path forward is an active effort from policymakers, cancer types and standardization of care through clinical practice guidelines in oncology. Moreover
https://www.nccn.org/docs/default-source/global/the-impact-of-policy-regulation-on-guideline-concordant-care-globally-summary-article.pdf?sfvrsn=b36df21a_3Chemotherapy Order Templates Reviewer Acknowledgement
Fred & Pamela Buffett Cancer Center Biliary Tract Cancers, Clinic Comprehensive Cancer Center Non-Small Cell Lung Cancer, Abramson Cancer Center at the University of Pennsylvania Small Cell Lung Cancer, Shira Dinner, MD Robert H. Lurie Comprehensive Cancer Center, University of Michigan Rogel Cancer Center Mark R. Litzow, MD
https://www.nccn.org/compendia-templates/nccn-templates-main/nccn-chemotherapy-order-reviewer-engagementAdvocacy December Toolkit_2021
Cholangiocarcinoma Foundation 4 Fight Colorectal Cancer 6 GO2 Foundation for Lung Cancer 7 ICAN, NCCN Digital Booklet of Patient Advocacy Resources National Comprehensive Cancer Network, , A c c e s s i b l e , a n d Equitable Cancer Care The NCCN Digital Resource Booklet includes, to precision medicine and address related needs for people with cancer. This Booklet was developed in conjunction with The National Comprehensive Cancer Network’s ® (NCCN ® ) Virtual Patient
https://www.nccn.org/docs/default-source/oncology-policy-program/advocacy-december-toolkit_2021.pdf?sfvrsn=4c2c60da_1CEO_Annual_Report_2024_to_BoD_March_2025
-specific and include breast cancer, non-small cell lung cancer, prostate cancer, colon cancer, and head, requests to the Non-Small Cell Lung Cancer panel and 80 requests each to the Breast Cancer and Colon, for Vietnam, focused on non-small cell lung cancer, was published in English and Vietnamese in 2024, guidelines for breast and liver cancers, as well as more cancer types in the future. Dr. Denlinger, Journal of the National Comprehensive Cancer Network (JNCCN)……………………25 Oncology Research Program
https://www.nccn.org/docs/default-source/member-institution/ceo_annual_report_2024_to_bod_march_2025.pdf?sfvrsn=a284d492_1NCCN_Oncology_Research_Program_Brochure
of patients with suspected or newly diagnosed lung cancer in Antelope Valley, one of the most underserved regions of Southern California. Antelope Valley has the highest rate of lung cancer mortality, of the first lung cancer screening program in Antelope Valley. This initiative has touched many, and treatment of lung cancer in this underserved area.” Dan J. Raz, MD City of Hope National Medical Center, that improve the lives of patients with cancer. National Comprehensive Cancer Network® Namrata Vijayvergia
https://www.nccn.org/docs/default-source/oncology-research-program-(orp)/nccn_oncology_research_program_brochure.pdf?sfvrsn=ebab0181_3NCCN Continuing Education Portal
Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer 1.00 AAPA, - Metastatic Castration-Resistant Prostate Cancer: Systemic Therapy Updates 1.00 AAPA Category 1 CME, $0.00 Patient Management Simulator: Treatment Recommendations for Kidney Cancer, $0.00 Vital Questions for Treatment of Bladder Cancer: Expert Insights on Recent, : 215.690.0280Copyright © 2025 National Comprehensive Cancer Network, All Rights Reserved Powered by the EthosCE
https://www.nccn.org/education-research/continuing-education-(ce)/continuing-education